Cardio-Renal Syndrome Type 4: Epidemiology, Pathophysiology and Treatment

Seminars in Nephrology

Volumn 32, Issue 1, 2012, Pages 40-48

  House, Andrew A ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Cardio Renal syndrome; Cardiovascular disease; Chronic kidney disease; Epidemiology; Renocardiac syndrome; Risk factors

Indexed keywords

ANTIANEMIC AGENT; CINACALCET; EZETIMIBE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ROSUVASTATIN; SIMVASTATIN; VITAMIN D;

ARTICLE; CARDIORENAL SYNDROME; CARDIORENAL SYNDROME TYPE 4; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; HEMODIALYSIS; HUMAN; MORTALITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

CARDIO-RENAL SYNDROME; HEART FAILURE; HEMATINICS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; VITAMINS;

EID: 84857392568     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2011.11.006     Document Type: Article

References (85)

1. House A.A., Anand I., Bellomo R., et al. Definition and classification of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 2010, 25:1416-1420.
2. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(Suppl 1):S1-S266. National Kidney Foundation.
3. Shastri S., Sarnak M.J. Cardiovascular disease and CKD: core curriculum 2010. Am J Kidney Dis 2010, 56:399-417.
4. Cheung A.K., Sarnak M.J., Yan G., et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004, 65:2380-2389.
5. Bagshaw S.M., Cruz D.N., Aspromonte N., et al. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 2010, 25:1406-1416.
6. Cruz D.N., Bagshaw S.M. Heart-kidney interaction: epidemiology of cardio-renal syndromes. Int J Nephrol 2010, 2011:351291.
7. Tonelli M., Wiebe N., Culleton B., et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006, 17:2034-2047.
8. Garg A.X., Clark W.F., Haynes R.B., House A.A. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002, 61:1486-1494.
9. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
10. Shastri S., Sarnak M.J. Cardiovascular disease and CKD: core curriculum 2010. Am J Kidney Dis 2010, 56:399-417.
11. Herzog C.A. Dismal long-term survival of dialysis patients after acute myocardial infarction: can we alter the outcome?. Nephrol Dial Transplant 2002, 17:7-10.
12. Gibson C.M., Dumaine R.L., Gelfand E.V., et al. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J 2004, 25:1998-2005.
13. Harnett J.D., Foley R.N., Kent G.M., et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995, 47:884-890.
14. Foley R.N., Parfrey P.S., Harnett J.D., et al. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995, 5:2024-2031.
15. Kottgen A., Russell S.D., Loehr L.R., et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2007, 18:1307-1315.
16. Shamseddin M.K., Parfrey P.S. Medscape: sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol 2011, 7:145-154.
17. Ganesh S.K., Stack A.G., Levin N.W., et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001, 12:2131-2138.
18. Pun P.H., Smarz T.R., Honeycutt E.F., et al. Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int 2009, 76:652-658.
19. Burton J.O., Korsheed S., Grundy B.J., McIntyre C.W. Hemodialysis-induced left ventricular dysfunction is associated with an increase in ventricular arrhythmias. Ren Fail 2008, 30:701-709.
20. Winkelmayer W.C., Patrick A.R., Liu J., et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 2011, 22:349-357.
21. Baber U., Howard V.J., Halperin J.L., et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Circ Arrhythm Electrophysiol 2011, 4:26-32.
22. Soliman E.Z., Prineas R.J., Go A.S., et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010, 159:1102-1107.
23. Ronco C., Haapio M., House A.A., et al. Cardio-Renal syndrome. J Am Coll Cardiol 2008, 52:1527-1539.
24. Ishani A., Grandits G.A., Grimm R.H., et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 2006, 17:1444-1452.
25. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355:2631-2639.
26. Blankenberg S., McQueen M.J., Smieja M., et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006, 114:201-208.
27. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
28. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994, 331:417-424.
29. Parikh S.V., de Lemos J.A. Biomarkers in cardiovascular disease: integrating pathophysiology into clinical practice. Am J Med Sci 2006, 332:186-197.
30. Austin W.J., Bhalla V., Hernandez-Arce I., et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006, 126:506-512.
31. Maisel A.S., Katz N., Hillege H.L., et al. Biomarkers in kidney and heart disease. Nephrol Dial Transplant 2011, 26:62-74.
32. Rattazzi M., Puato M., Faggin E., et al. New markers of accelerated atherosclerosis in end-stage renal disease. J Nephrol 2003, 16:11-20.
33. Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 2006, 11:36-41.
34. Verma S., Kuliszewski M.A., Li S.H., et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004, 109:2058-2067.
35. Zsuga J., Gesztelyi R., Torok J., et al. Asymmetric dimethylarginine: a molecule responsible for the coexistence of insulin resistance and atherosclerosis via dual nitric oxide synthase inhibition. Med Hypotheses 2005, 65:1091-1098.
36. Ravani P., Tripepi G., Malberti F., et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005, 16:2449-2455.
37. Olgaard K., Lewin E., Silver J. Calcimimetics, vitamin D and ADVANCE in the management of CKD-MBD. Nephrol Dial Transplant 2011, 26:1117-1119.
38. Urquhart B.L., House A.A. Assessing plasma total homocysteine in patients with end-stage renal disease. Perit Dial Int 2007, 27:476-488.
39. Block G.A., Klassen P.S., Lazarus J.M., et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15:2208-2218.
40. Bostom A.G., Kronenberg F., Jacques P.F., et al. Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: critical impact of true glomerular filtration rate. Atherosclerosis 2001, 159:219-223.
41. Busch M., Franke S., Muller A., et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004, 66:338-347.
42. Pifer T.B., McCullough K.P., Port F.K., et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002, 62:2238-2245.
43. Levin A., Thompson C.R., Ethier J., et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999, 34:125-134.
44. Meyer T.W., Hostetter T.H. Uremia. N Engl J Med 2007, 357:1316-1325.
45. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32(Suppl 3):S112-S119.
46. Fort J. Chronic renal failure: a cardiovascular risk factor. Kidney Int Suppl 2005, 99:S25-S29.
47. Schiffrin E.L., Lipman M.L., Mann J.F. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116:85-97.
48. Bologa R.M., Levine D.M., Parker T.S., et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998, 32:107-114.
49. Wratten M.L., Galaris D., Tetta C., Sevanian A. Evolution of oxidative stress and inflammation during hemodialysis and their contribution to cardiovascular disease. Antioxid Redox Signal 2002, 4:935-944.
50. Sarnak M.J., Coronado B.E., Greene T., et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002, 57:327-335.
51. Panichi V., Maggiore U., Taccola D., et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004, 19:1154-1160.
52. Pozzoni P., Del Vecchio L., Pontoriero G., et al. Long-term outcome in hemodialysis: morbidity and mortality. J Nephrol 2004, (Suppl 8):S87-S95.
53. Zoccali C., Mallamaci F., Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl 2003, 85:S105-S110.
54. Stenvinkel P., Barany P., Heimburger O., et al. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6?. Kidney Int Suppl 2002, 80:103-108.
55. Zimmermann J., Herrlinger S., Pruy A., et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999, 55:648-658.
56. MacRae J.M., Pandeya S., Humen D.P., et al. Arteriovenous fistula-associated high-output cardiac failure: a review of mechanisms. Am J Kidney Dis 2004, 43:e17-e22.
57. Chan C.T., Levin N.W., Chertow G.M., et al. Determinants of cardiac autonomic dysfunction in ESRD. Clin J Am Soc Nephrol 2010, 5:1821-1827.
58. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
59. Culleton B.F., Hemmelgarn B. Inadequate treatment of cardiovascular disease and cardiovascular disease risk factors in dialysis patients: a commentary. Semin Dial 2004, 17:342-345.
60. Locatelli F., Pisoni R.L., Combe C., et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004, 19:121-132.
61. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
62. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084.
63. Pfeffer M.A., Burdmann E.A., Chen C.Y., et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361:2019-2032.
64. Besarab A., Goodkin D.A., Nissenson A.R. The normal hematocrit study-follow-up. N Engl J Med 2008, 358:433-434. Normal Hematocrit Cardiac Trial Authors.
65. Palmer S.C., Navaneethan S.D., Craig J.C., et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010, 153:23-33.
66. Wrone E.M., Hornberger J.M., Zehnder J.L., et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004, 15:420-426.
67. Jamison R.L., Hartigan P., Kaufman J.S., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007, 298:1163-1170.
68. Urquhart B.L., Freeman D.J., Spence J.D., House A.A. The effect of mesna on plasma total homocysteine concentration in hemodialysis patients. Am J Kidney Dis 2007, 49:109-117.
69. House A.A., Eliasziw M., Cattran D.C., et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010, 303:1603-1609.
70. Bostom A.G., Carpenter M.A., Kusek J.W., et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation 2011, 123:1763-1770.
71. Mathew S., Davies M., Lund R., et al. Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease. Eur J Clin Invest 2006, 36(Suppl 2):43-50.
72. Navaneethan S.D., Palmer S.C., Vecchio M., et al. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev 2011, 2. CD006023.
73. Suki W.N., Zabaneh R., Cangiano J.L., et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007, 72:1130-1137.
74. Garside R., Pitt M., Anderson R., et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess 2007, 11:iii. xi-xiii, 1-167.
75. Chertow G.M., Pupim L.B., Block G.A., et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007, 2:898-905.
76. Andress D.L. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006, 69:33-43.
77. Freundlich M., Quiroz Y., Zhang Z., et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008, 74:1394-1402.
78. Brown A.J., Slatopolsky E. Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol Aspects Med 2008, 29:433-452.
79. Lee G.H., Benner D., Regidor D.L., Kalantar-Zadeh K. Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr 2007, 17:38-44.
80. Navaneethan S.D., Palmer S.C., Schreiber M.J., Strippoli G.F. Weighing the evidence for treatment of chronic kidney disease mineral and bone disorder. Nephrology (Carlton) 2009, 14:363-366.
81. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
82. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
83. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377(9784):2181-2192.
84. Chertow G.M., Levin N.W., et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010, 363:2287-2300. FHN Trial Group.
85. Gaede P., Lund-Andersen H., Parving H.H., Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.